
HTGF et al. back in Epivios
High-Tech Gründerfonds (HTGF) and the investment arm of Life Science Inkubator have invested in German epigenetics specialist Epivios, alongside Technology Transfer Heinrich Heine University and a private investor.
The seed financing will help further the development of the company's cancer-testing technology through the expansion of the laboratory and the team. It will also allow the team to execute preliminary clinical validation studies. HTGF typically invests €500,000 in seed rounds.
Company
Epivios span out of Heinrich Heine University of Düsseldorf in 2011. The team, composed of the company's five founders, works on developing molecular diagnostic cancer tests for early discovery and exact diagnosis.
Their innovation is based on a new epigenetic procedure that can show changes in DNA methylation patterns. The company is based in Düsseldorf.
People
Dr Jörg Fregien worked on the deal as managing director of LSI Pre-Seed Fund. Ron Winker is investment manager at HTGF.
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater